Skip to main content

Table 5 Acceptance of ACT and discounts (N = 164, excl. orphan drugs)

From: Benefit assessment in Germany: implications for price discounts

Acceptance of ACT set by GBA: no           
Additional benefit category ACT ≤ 1      ACT > 1     
  n Mean Min Max SD n Mean Min Max SD
Overall 37 20.25 3.40 67.30 13.21 30 22.46 0.00 53.71 11.88
Overall with additional benefit 18 16.63 4.74 39.65 10.05 9 19.72 0.00 51.67 15.30
Considerable 7 18.05 10.07 32.87 7.93 4 15.06 10.07 23.15 6.29
Minor 8 16.70 4.74 39.65 13.26 5 23.45 0.00 51.67 19.99
Non-quantifiable 3 13.16 10.07 19.35 5.36 0
No 19 20.25 3.40 67.30 13.21 21 23.63 3.16 53.71 10.30
Acceptance of ACT set by GBA: yes
Additional benefit category ACT ≤ 1      ACT > 1     
  n Mean Min Max SD n Mean Min Max SD
Overall 44 24.14 0.00 78.02 15.22 53 23.07 2.01 58.73 14.25
Overall with additional benefit 17 23.26 6.35 35.19 12.60 27 22.05 2.01 58.73 14.69
Major 1 13.64 13.64 13.64 0
Considerable 7 19.05 6.35 35.19 11.70 8 29.08 10.38 42.54 14.21
Minor 7 31.58 19.80 46.44 11.77 15 18.78 2.01 58.73 16.10
Non-quantifiable 2 13.64 13.64 13.64 0.00 4 20.25 19.25 21.25 1.15
No 27 24.69 0.00 78.02 16.86 25 24.73 2.01 49.52 13.92
Additional harm potential 0 1 9.00 9.00 9.00
  1. Abbreviations: Min minimum, Max maximum, SD standard deviation
  2. All discounts presented in %